Search Results

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 Cell and Gene Meeting on the Med, to be held from April 9-11, 2024 in Rome, Italy.

ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced that it will present new preclinical data supporting the potential therapeutic benefit of IMPT-514 for the treatment of multiple sclerosis (MS).

ImmPACT Bio USA , Inc. today announced that it will participate at the BIO Investor Forum, to be held from October 17-18, 2023 in San Francisco, CA.

ImmPACT Bio USA , Inc. today announced it has been named on the BioSpace 2024 Best Places to Work small employer list.

ImmPACT Bio USA , Inc. today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023.

ImmPACT Bio USA Inc. (ImmPACT Bio) today announced that it will present new ex vivo preclinical data for ImmPACT Bio’s bispecific Claudin 18.2 (CLDN18.2)/TGF-β chimeric antigen receptor (CAR) T program for the treatment of solid tumors that express CLDN18.2, including gastric and gastroesophageal junction cancer, as part of a poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting.

ImmPACT Bio USA , Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023.

Accurus Biosciences Inc. (“Accurus”) is pleased to announce that it has entered into a worldwide licensing agreement for its CLDN18.2 monoclonal antibody with ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company focusing on the development of next generation chimeric antigen receptor (CAR) T-cell therapies.